Breast cancer incidence and predictions (Monastir, Tunisia: 2002-2030): A registry-based study.

INTRODUCTION: Breast cancer is a major public health problem worldwide. It is the leading cause of cancer deaths in females. In developing countries like Tunisia, the frequency of this cancer is still growing. The aim of this study was to determine the crude and standardized incidence rates, trends and predictions until 2030 of breast cancer incidence rates in a Tunisian governorate.
METHODS: This is a descriptive study including all female patients diagnosed with breast cancer in Monastir between 2002 and 2013. The data were collected from the cancer register of the center. Tumors were coded according to the 10th version of international classification of disease (ICD-10). Trends and predictions until 2030 were calculated using Poisson linear regression.
RESULTS: A total of 1028 cases of female breast cancer were recorded. The median age of patients was 49 years (IQR: 41-59 years) with a minimum of 16 years and a maximum of 93 years. The age-standardized incidence rate (ASR) was of 39.12 per 100000 inhabitants. It increased significantly between 2002 and 2013 with APC of 8.4% (95% CI: 4.9; 11.9). Prediction until 2030 showed that ASR would reach 108.77 (95% CI: 57.13-209.10) per 100000 inhabitants.
CONCLUSION: The incidence and the chronological trends of breast cancer highlighted that this disease is of a serious concern in Tunisia. Strengthening preventive measures is a primary step to restrain its burden.

Introduction

Breast cancer is a major public health problem worldwide. It is the most common cancer in women. Among females’ malignant neoplasms, it represents the leading cause of preventable cancer deaths in the world [1]. The Global Cancer Observatory (GCO) database estimates that there were 2 261 419 new female breast cancer cases and 684 996 related deaths in 2020 [2]. Moreover, morbidities generated by this cancer as well as the cost of therapies used make it a heavy health, social and economic burden.

It is commonly recognized that high incidence rates were observed in developed countries, whereas the mortality rate was high in low-middle income countries [3,4]. However, the rapid pace of urbanization in developing countries in the last decades, has created changes in many disease patterns. The incidence of breast cancer has been steadily increasing and is currently facing unexpected challenges in management [5]. Moreover in these countries and specifically in North African countries breast cancer is characterized by an earlier age, an advanced stage at presentation and more aggressive subtypes compared to Western countries [6].

Hence, preventing this cancer is among the public health priorities. Assessing cancer patterns and trends is essential for setting the health care priorities, identifying targets for intervention as well as guiding further research [7,8]. Thus, the availability of cancer data is a key element in setting up a program to fight this disease. Thus, implementing registers which provide reliable information on the cancer profile is essential. As such, in 1966, the International Association of Cancer Registries (IACR) was created [9].

In Tunisia, breast cancer is the first female cancer and represents the leading cause of cancer-related deaths (19.7%) [10]. According to the GCO, the number of Tunisian new cases of breast cancer in 2020 was of 3092 (34.5% of all female cancers) [11]. Three Tunisian cancer registers were created in 1987 (North, Center, and South). However, data issued from these registers are not being updated. The latest estimations of 2020 available in the GCO were generated from the Northern registry (2008–2010) and the central registry (2003–2007) [2]. The most recent studies describing the actual field data on breast cancer in Tunisia are based on these old data. All other recent publications on breast cancer epidemiology in Tunisia are based solely on estimates from the Global cancer observatory.

The aim of this work was to determine the crude and standardized incidence rates, trends over a period of 12 years (2002–2013) and predictions until 2030 of breast cancer incidence rates in Monastir governorate based on data from a population based cancer registry.

Methods

Study design

This is a descriptive study including all female patients diagnosed with breast cancer in Monastir between 2002 and 2013.

Setting

Monastir Governorate is one of the twenty-four governorates of Tunisia. It is located on the north-eastern coast of Tunisia. It is an industrial governorate with several industries including textile, brick, and soap factories. It covers an area of 1019 km2 (393 m2) and is divided into thirteen delegations. In 2014, the female population of Monastir counted for 274 613 persons and represented 5% of the female Tunisian population and 22% of the female population of the center region of the country composed of six governorates: Sousse, Monastir, Mahdia, Kairouan, Kasserine and Sidi Bouzid. Data about cancer incidence in Monastir is recorded continuously in a population-based register (the center registry of cancer) which is a regional registry that records cancer data for the above cited six governorates. However, latest data published from this registry dates from 2003–2007 [2].

Participants

We analyzed all breast cancer new cases residents in Monastir Governorate from January 2002 to December 2013. Male breast cancer cases were excluded from our analysis.

Data collection

Female breast cancer new cases in Monastir were selected from the cancer register of the center between 2002 and 2013 according to the 10th version of international classification of diseases (ICD-10) [12]. Verification of data conformity between cases recorded in the center registry of cancer and cases recorded in Monastir health care centers was carried out by the team of the Department of Epidemiology and Preventive Medicine of Monastir University Hospital.

Variables

Data included variables related to age, date of first diagnosis and residential address.

Statistical analysis

Data were verified and analyzed using IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: IBM Corp and Microsoft Excel. The crude incidence rate (CIR) of breast cancer was calculated based on Tunisian National Institute of Statistics data and was expressed per 100,000 person-years [13]. As we have included only females with new breast cancer in our study, we used female population as denominator. The age standardized incidence rate (ASR) per 100,000 person-years was calculated using the world standard population according to the World Health Organization statement of 2013 [14]. To test trends of the CIR we have calculated the Annual Percentage Change (APC) using Join point regression program. We estimated 2030 breast cancer incidence predictions using the Age Period Cohort analysis based on Poisson log linear regression. A p-value < 0.05 was considered statistically significant.

Ethical considerations

The study was conducted according to ethical standards collections. To maintain the principle of confidentiality, the data used were anonymized. Ethics approval for the conduct of the research was gained from the Ethics Committee of the faculty of medicine of Monastir (Reference Number: IORG0009738N°101/OMB0990-0279).

Results

A total of 1028 cases of female breast cancer were collected which represented 27.4% of all female cancer cases recorded in Monastir Governorate from January 2002 to December 2013. The median age of patients was of 49 years (IQR: 41–59 years) with a minimum of 16 years and a maximum of 93 years (Fig 1). About 10.5% and 23% of breast cancer cases occurred in women under 35 years old and under 40 years respectively (Fig 2).

Fig 1

Age of diagnosis of breast cancer (Monastir, 2002–2013).

Fig 2

Distribution of female breast cancer new cases according to the age of diagnosis (Monastir, 2002–2013).

Crude and standardized incidence rates of breast cancer

The crude incidence rate was of 34,25 per 100000 inhabitants. The highest CIR was noted for patients aged between 40 and 59 years (101.7 per 100000 inhabitants) (Fig 3). The age-standardized incidence rate (ASR) was of 39.12 per 100000 inhabitants.

Fig 3

Crude incidence rate of breast cancer by age group (Monastir, 2002–2013).

Trends and predictions

Breast cancer incidence increased significantly between 2002 and 2013 with APC of 8% (95% CI: 4.6; 11.6) for crude incidence rate and 8.4% (95% CI: 4.9; 11.9) for Standardized incidence rate (Fig 4). With regard to age group, trends for patients aged more than 40 years increased significantly during the study period (Table 1).

Fig 4

The annual percentage change (APC) of breast cancer crude and standardized incidence rates (Monastir, 2002–2013).

Table 1

The annual percentage change (APC) of female breast cancer crude incidence rate by age group (Monastir, 2002–2013).

Age class (Years)	CIR (/105)*		APC (%)	CI 95%
	2002	2013
20–39	11.42	25.13	+2.7 (p = 0.3)	[-3.7; +9.6]
40–59	66.49	169.44	+8.7 (p<0.001)	[+5.8; +12.2]
≥ 60	59.73	191.99	+10.9 (p<0.001)	[+5.2; +16.9]

*CIR: Crude Incidence Rate (/105 person-years).

Prediction until 2030 showed that CIR would reach 123.76 (95% CI: 64.76–238.96) and ASR would reach 108.77 (95% CI: 57.13–209.10) per 100000 inhabitants (Table 2). Predictions according age group are shown in Table 3.

Table 2

Projection of female breast cancer crude and standardized incidence rates per 105 person-years until to 2030 in the Monastir region.

Year	N	95% CI		CIR*	95% CI		SIR**	95% CI
		Lower limit	Upper limit		Lower limit	Upper limit		Lower limit	Upper limit
2016	158	123.37	203.09	55.16	42.89	70.61	56.7	44.13	72.63
2017	171	129.69	225.44	58.3	44.13	76.71	59.44	44.98	78.19
2018	185	136.33	250.5	61.68	45.42	83.47	62.24	45.82	84.21
2019	200	143.34	278.57	65.42	46.86	91.08	65.44	46.84	91.12
2020	216	150.75	310.01	69.24	48.23	99.19	68.16	47.45	97.65
2021	234	158.56	345.24	73.33	49.66	108.14	71.54	48.42	105.51
2022	253	166.84	384.71	77.68	51.15	117.95	74.93	49.32	113.78
2023	274	175.59	428.96	82.29	52.68	128.7	78.49	50.22	122.72
2024	297	184.84	478.58	87.21	54.25	140.47	82.23	51.15	132.38
2025	322	194.64	534.22	92.42	55.88	153.37	86.14	52.09	142.82
2026	349	205.01	596.66	97.96	57.55	167.5	90.25	53.06	154.1
2027	378	215.99	666.74	103.84	59.28	182.99	94.55	54.04	166.3
2028	410	227.6	745.44	110.08	61.05	199.96	99.07	55.04	179.47
2029	445	239.91	833.83	116.72	62.88	218.56	103.81	56.08	193.71
2030	483	252.92	933.16	123.76	64.76	238.96	108.77	57.13	209.1

*CIR: Crude Incidence Rate (/105 person-years).

**SIR: Standardized Incidence Rate (/105 person-years).

Table 3

Projection of female breast cancer crude rates (/105 person-years) by age group until to 2030 in the Monastir region.

Year	20–39			40–59			≥ 60
	CIR*	95% CI		CIR*	95% CI		CIR*	95% CI
		Lower limit	Upper limit		Lower limit	Upper limit		Lower limit	Upper limit
2016	22.15	15.61	31.42	143.36	117.27	175.23	151.29	112.50	203.40
2020	24.59	14.93	40.46	174.06	130.01	233.04	183.17	118.70	282.64
2025	27.93	14.01	55.68	222.06	147.49	334.35	235.54	127.74	434.28
2030	31.82	13.15	77.01	283.05	166.90	480.01	301.07	136.34	664.84

*CIR: Crude Incidence Rate (/105 person-years).

Discussion

Disparities between countries in terms of the epidemiology and the management of breast cancer are well known. However, it remains a rising public health problem globally. The present study described the epidemiology and trends of breast cancer in Monastir Governorate from 2002 to 2013 with projection to 2030.

The ASR of female breast cancer in Monastir was of 39.12 per 100000 inhabitants. Our results showed a higher incidence rate than that reported in the Center of Tunisia between 1993-2007(ASR of 29.2 per 100,000) and the North of Tunisia between 2007–2009 (ASR:35.1/100 000) [15,16]. In addition, compared to the GCO 2012 estimations, our findings were higher than the rate observed previously in the global Tunisian population (ASR: 31.8 per 100 000). These data raise the hypothesis of a higher breast cancer incidence rate in Monastir in comparison to the national rate. This may be partly attributable to the industrialized feature of the region with higher air pollution levels and an urbanized lifestyle. Comparison with results from other neighboring countries showed higher rates in Northern Africa and Western Asia (43.2 and 42.8 per 100 000 respectively) [17]. When comparing with statistics in developed countries, much higher incidence rates were observed in very high Human Development Index (HDI) countries led by the Netherlands (117.2/100,000) [2,18,19]. In France, breast cancer remains the most frequent cancer in women with an ASR of 92.2 per 100,000 in 2007 [20]. In 2010, based on cases diagnosed from 17 surveillance, epidemiology, and end results (SEER) geographic areas, the United States reported that the ASR of female breast cancer was 126.02 per 100,000 women [21]. In Russia the ASR was of 45.6 per 100 000 between 2009–2013 [7] However, the incidence rate reported in our study remains superior to rates reported from South-central Asia and Eastern Asia, (ASR: 27–28.2) [19]. These differences are in accordance with the literature. Indeed, breast cancer is most frequent among developed countries than developing ones, whereas the mortality rate is higher in low/medium HDI countries [7,22,23]. This can be partially explained by a more protective risk profile in low- and middle-income countries especially North-Africa than in Western countries. The efficiency of the screening programs in Western countries may also explain this difference [6].

Nevertheless, female breast cancer had a significant increasing trend with an APC of 8% between 2002–2013 and ASR was predicted to be increased to 108.77 (95% CI: 57.13–209.10) per 100000 inhabitants.

These results are consistent with previous Tunisian reports on breast cancer. Indeed, from 1993–2007 a positive trend was noted (+2.5%) in Central Tunisia and Northern Tunisia (an APC of 1.5% between 1994–2009) [15,16]. Moreover according to the GCO estimations the incidence of breast cancer would continue to increase in Tunisia and would reach 370 per 100000 inhabitants in 2030 [16,24].

However, according to this study a decrease was noted in 2012 which can be explained mainly by the lower quality of notification and the screening program during this period marked by the Tunisian revolution and the political and economic instability. Cases which were not registered during 2012 were notified in 2013. That is why, a sharp increase in the incidence rate during 2013 was recorded.

Worldwide, incidence rates of breast cancer are rising fast in transitioning countries. According to Lima SM et al, Middle East North Africa had the largest per-year increase in overall incidence between1990 and 2017 (APC = 2.38, 95% CI = 2.29, 2.47) [25]. Sung H et al reported that some of the most rapid increases are occurring in sub-Saharan Africa with an increase rate >5% per year in Malawi (Blantyre), Nigeria (Ibadan), and the Seychelles and of 3% to 4% per year in South Africa between the mid-1990s and the mid-2010s. Rates are rising also in transitioning Asian countries as well as in some high-income Asian countries (Japan and the Republic of Korea) [26,27] where rates are historically low but expected to continue to increase [28]. This increase can be linked to a number of risk factors such as changes in lifestyle and reproductive factors related to growing economies and the increase in the proportion of women in the industrial workforce (Diet, greater levels of excess body weight, physical inactivity, postponement of childbearing, having fewer children and lower breastfeeding…) [29] and have resulted in a convergence toward the risk factor profile of western countries and narrowing international gaps in breast cancer morbidity [26]. By contrast, several reports documented recent declines in the incidence of breast cancer in the US and throughout developed countries [25,30,31]. In fact, during the early 2000s, incidence dropped or stabilized [32] largely due to a reduction in the use of menopausal hormone therapy and a plateau in screening participation [33,34]. But since 2007, a slow upturn in incidence rates has been notified in the United States (<0.5% annually) [35] and in many other European countries [27]. This increase was limited to estrogen receptor-positive cancer which was attributed to the obesity epidemic, given the strong association between overweight and estrogen receptor-positive cancer [36,37]. According to Rahib L et al, breast cancer is projected to remain the first female cancer by 2040 in US [38]. The decline in breast cancer incidence rates has also been demonstrated using machine learning prediction models in the European continent. In fact, when the incidence rates of 2012 were considered, only two countries, Switzerland and Italy had increasing incidence rates for Breast Cancer in 2020 (1.0% and 1.8% respectively). However, fluctuations occurred for Austria during the period between 2014 and 2019. All other countries have stable reductions of incidence rates during this period [39].

With regard to age group, our results showed that the highest increase was shown for women aged more than 60 years. Findings from other developing countries like Pakistan showed large increases in breast cancer rates among women aged 50 to 64 years [40]. Lima SM et al analyzed trends of breast cancer incidence in 182 countries in the world between 1990 and 2017. Their results showed that the largest increase in incidence rate was in women under 50 years. Among this age group, the APC was of 1.55% worldwide and the largest increase rate was in Middle East and North Africa with 2.63% of APC [25].

In addition to the high increasing incidence of female breast cancer, this work highlights the young age at diagnosis. Indeed the median age was 49 years (IQR: 41–59 years) which is close to previous findings from Tunisia [15,41] and from other Arabic countries, such as Emirates, Oman, and Qatar [42]. The median age reported here was younger than that described in most developed countries such as in the US (median age: 61 years) [43]. In our study, about 10.5% of breast cancer cases occurred in women under 35 years old. In other Tunisian studies, this percentage ranged from 6.7% to 17% [15,16,41]. Whereas, in western countries the majority of breast cancer cases occurs in women aged more than 50 years [3,20,43]. This result was in accordance with many reports from developing countries sharing the fact that breast cancer occurs in a younger population as compared to the west which can be explained partially by the young age pyramid in LMICs [44]. Knowing that breast cancer in young female tends to be more aggressive and may be associated with an increased risk for contralateral breast cancer, this age group should have a special attention to improve prevention, diagnosis and prognosis [45].

Limitations

To the best of our knowledge this is the first study in Monastir describing the incidence and chronological trends of female breast cancer over a period of 12 years. Nevertheless, it had some limitations. Indeed, our analysis used demographic data from the 2004 and 2014 Tunisian National Institute of Statistics Census and data on the population estimate in other years were given through projections. Another limitation is that a selection bias may be observed due to the lack of notification of private sector cancer new cases. That would slightly underestimate the real cancer incidence in Monastir governorate. Additionally, mortality which is an important epidemiological indicator of disease severity was not studied due to the lack of data.

Conclusion

In conclusion, breast cancer had a relatively high incidence in Monastir comparing to other Tunisian regions with an earlier age at diagnosis and increasing trends over time. Thus, this disease is of a serious concern in Tunisia particularly in Monastir. Strengthening preventive measures is a primary step to hold this burden. It includes the revision of the current screening and management strategies of breast cancer. Moreover, this study underlines the importance of focusing on early detection of breast cancer. Also, intensifying public awareness campaigns and improving health care delivery system could reduce the increasing trend of the disease and its socio-economic burden. Moreover, the control of breast cancer would provide a great opportunity for further reduction of cervical cancer as well as the control of other cancers and non-communicable diseases known to share similar risk factors with breast cancer.

Female breast cancer new cases in Monastir between 2002 and 2013.

(XLSX)

Click here for additional data file.

21 Jan 2022

1 Apr 2022

Response to Reviewers

Dear Editor,

Thank you for your attention to our work. The comments and suggestions we have received are valuable and very helpful to improve our manuscript. We have made revisions based on your latest comments and suggestions, as described in the authors' response.

We respond in detail to each of the reviewers’ comments. They raised important issues and we agree with almost all their comments. We have revised our manuscript according to their indications. We hope that they will find our responses to their comments satisfactory, and we are willing to finish the revised version of the manuscript including any further suggestion that the reviewers may have. The revision has been developed in consultation with all coauthors, and each author has given approval to the final form of this revision. All changes made in the revised version will be visible in red.

Please find as attached files:

The “Response to Reviewers”,

the “'Revised Manuscript with Track Change” and

the “Manuscript” (the unmarked version of the revised manuscript).

We sincerely hope that the revision of the manuscript will be satisfactory and the enclosed version will be acceptable for publication.

Once again thank you for your cooperation.

Sincerely Yours,

Dr Imen ZEMNI

Journal Requirements:

1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming.

Response: Thank you. We did the required modifications.

2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found.

Response: Thank you. We attached an Excel supplementary file intitled “S1 File. Female breast cancer new cases in Monastir between 2002 and 2013” in Supporting Information. (Lines 461 and 462)

3. PLOS requires an ORCID iD for the corresponding author in Editorial Manager on papers submitted after December 6th, 2016. Please ensure that you have an ORCID iD and that it is validated in Editorial Manager.

Response: Thank you. We indicated the ORCID iD of the corresponding author.

4. Please review your reference list to ensure that it is complete and correct.

Response: Thank you. We reviewed the reference list and added other references as it was recommended by reviewer 2.

Review Comments:

Reviewer 1:

1. Abstract: The second line "Among females'.....causing mortality" needs rephrasing.

Response: Thank you. We did the necessary modifications. (Lines 32 and 33)

2. For the worldwide readers, it would be better that the spelling of "Crud" as in crude incidence rate be written uniformly as "Crude".

Response: Thank you. We did the necessary modifications. (Lines 82,113,141,142,145,149 and 305)

3. In methodology section, As you have included only females with new breast cancer in your study, (Male breast cancer cases were excluded), it is not clear that you used sex specific population as denominator or not. The title of the relevant tables should also mention the word "females".

Response: Thank you. As we have included only females with new breast cancer in our study, we used female population as denominator. We added this information in the methodology section (Lines 115 and 116). We also mentioned the word "female" in the titles of the relevant tables (Lines 155,161 and 179).

4. The time point of the population used as denominator (eg mid-year...or something else ) is not mentioned.

Response: Thank you. We computed the point incidence rate of breast cancer (per 100,000 population) for each year based on the Tunisian National Institute of Statistics data. Incidence rates were expressed per 100,000 person-years: The Tunisian National Institute of Statistics carries out censuses of the Tunisian population every 10 years. The last censuses were carried out between April and May 2014. Data on the population estimate in other years are given through projections made by the Tunisian National Institute of Statistics.

5. Statistical analysis section should mention the full details of the SPSS software used like the city, country etc.

Response: Thank you. We did the necessary modifications. (Lines 112 and 113)

6. In discussion section, Spelling of "contralateral"

Response: Thank you. We corrected the spelling. (Line 276)

Reviewer 2:

1. The methodology is adequate, but I could not locate the ethics committee recommendations or consent.

Response: Thank you. We mentioned in the methodology section that the protocol of this study was approved by the ethics Committee of the faculty of medicine of Monastir (Reference Number: IORG0009738N°101/OMB0990-0279).) (Lines 124,125 and 126)

2. The discussion in this paper is a momentous tasks and needs more trends to be discussed worldwide, although the authors have tried to reason well that why Monastir has higher breast cancer incidence rate in comparison to the national rate and how does it stand globally. May I suggest more scientific discussions to the authors. You are also requested to compare with predictions from Machine Learning Models.

Response: Thank you. We revised the discussion and we added paragraphs to discuss:

�  The incidence rate in Monastir comparatively to other national results and international findings (lines 201-211).

�  Trends of breast cancer incidence comparatively to last reports from Tunisia and to statistics from the different regions in the World (Lines 230-257).

�  Trends according age groups (Line 258-267).

3. There were no limitations and biases mentioned in the paper and authors are requested to add them as well.

Response: Thank you. We added a paragraph for limitations at the end of the manuscript (Lines 279-287).

4. Spelling errors noted (crud = crude)

Response: Thank you. We did the necessary modifications. (Lines 82,112,136,137,144 and 264)

Submitted filename: Response-to-Reviewers.docx

Click here for additional data file.

21 Apr 2022

Breast cancer incidence and predictions (Monastir, Tunisia: 2002-2030): A registry-based study

PONE-D-21-39057R1

Dear Dr. Imen Zemni ,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

Gopal Ashish Sharma, MBBS, MD

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Revised manuscript is accepted for publication as both the reviewers had conveyed the accepatnce of changes proposed through journal and available electronic means.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: I thanks all the authors for considering our suggestions regarding the revision and further improvement of this manuscript.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Dr. Vijay Kumar Barwal, IGMC Shimla, India

16 May 2022

PONE-D-21-39057R1

Breast cancer incidence and predictions (Monastir, Tunisia: 2002-2030): A registry-based study

Dear Dr. Zemni:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. Gopal Ashish Sharma

Academic Editor

PLOS ONE